MedTrace Logo

Kidney Damage in Patients Receiving Cisplatin and Ifosfamide for Solid Tumors

NCT00695032 · Status: SUSPENDED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2014-11-05

No results posted yet for this study

Summary

RATIONALE: Studying samples of blood and urine from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment.

PURPOSE: This research study is evaluating kidney damage in patients receiving cisplatin and ifosfamide for solid tumors.

Conditions

  • Chemotherapeutic Agent Toxicity
  • Renal Toxicity
  • Unspecified Adult Solid Tumor, Protocol Specific

Interventions

DRUG

cisplatin

DRUG

ifosfamide

OTHER

laboratory biomarker analysis

Sponsors & Collaborators

  • Institut Claudius Regaud

    lead OTHER

Principal Investigators

  • Christine Chevreau-Dalbianco, MD · Institut Claudius Regaud

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-10-31
Primary Completion
2012-09-30

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00695032 on ClinicalTrials.gov